PDF   Print   View All
July 25, 2002
HEMISPHERX ANNOUNCES CONFERENCE CALENDAR
Hemispherx Biopharma to Present at Several Scientific and Financial Conferences


Philadelphia, PA, Thursday, July 25, 2002: Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome announced today that it intends to present at several scientific and financial conferences in the coming months.

At these conferences, the Company plans to present the new data regarding its two ongoing phase IIb clinical trials for HIV/AIDS. The first trial AMP 719, is an experimental Salvage Therapy and is designed to evaluate the potential synergistic efficacy of the Company’s lead product, Ampligen, as an adjunct to HAART regimens. The second trial, AMP 720, is designed to evaluate the effects of Ampligen under Strategic Treatment Intervention (STI).

Hemispherx is submitting abstracts for presentation at several HIV/AIDS conferences such as:

42nd ICAAC, September 27-30, 2002 in San Diego, California. The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the world’s premier meeting on infectious diseases and antimicrobial agents, organized by the American Society for Microbiology. More than 12,000 scientists from around the world participate in ICAAC to exchange information and foster global solutions to the challenges of HIV/AIDS and other topics.

HIV DART 2002, December 15-19, 2002 at the Ritz-Carlton in Naples, Florida. The conference uniquely blends the areas of biology, chemistry, pharmacology, and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection.

Hemispherx will present at several financial and investor meetings such as:

Wall Street Reporter Roundtable, July 31, 2002 in New York. This Biotech Roundtable of biotech CEO’s and biotechnology analysts, representing investment firms such as C.E. Unterberg Towbin, Dresdner Kleinwort Wasserstein, Roth Capital Partners, Needham & Company, Raymond James & Associates, will listen to three biotech panel speakers, of which Dr. William Carter is one of them. Following the meeting there will be published a report including a transcript of the Roundtable, an interview with Dr. Carter and a full investment profile of the Company.

Wall Street Analyst Forum, September 9-13, 2002 in New York. Hemispherx will present on September 9th at 11.40 am at this Institutional Investor Conference. CCBN will provide a live and retrievable web cast of our presentation to the global investment community.

These meetings represent the first steps in a expanded program of attendance at financial conferences, analyst forums and investor meetings.

The Company will provide additional information about these conferences and other events at due time.

ABOUT HEMISPHERX

Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS).


Contact(s):
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554

Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Robert Giordano, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.